On April 23, 2021, the U.S. Food and Drug Administration (FDA) approved the Ventana MMR RxDx Panel for patients with advanced or recurrent endometrial cancer. Testing can identify patients eligible for treatment with dostarlimab-gxly, which was also approved by the FDA on April 22, 2021.
Read Roche's announcement.
Posted 4/23/2021
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
